LEVIN ARTHUR A 4
4 · Avidity Biosciences, Inc. · Filed Jan 23, 2026
Research Summary
AI-generated summary of this filing
Avidity (RNA) Director Arthur Levin Sells 1,758 Shares
What Happened Arthur A. Levin, a director of Avidity Biosciences, sold 1,758 shares of common stock on January 21, 2026, at $72.45 per share for gross proceeds of $127,367. The sale was reported on Form 4 filed January 23, 2026. This was a sale (not a purchase) and appears to be routine.
Key Details
- Transaction type: Sale (Code S) — open market or private sale on 2026-01-21
- Price and value: 1,758 shares × $72.45 = $127,367 (gross)
- Filing: Form 4 filed 2026-01-23 (filed two days after the transaction; appears timely)
- Shares owned after transaction: Not specified in the provided excerpt
- Footnote: Sale was a mandatory "sell-to-cover" to satisfy tax withholding on RSU vesting (RSUs vested Jan 20, 2026). The Reporting Person executed an instruction letter for automatic sale and cites the issuer’s sell-to-cover election; the transaction was intended to satisfy Rule 10b5-1 affirmative defense conditions and was not a discretionary trade.
Context This was a tax-withholding related sell-to-cover of RSU proceeds rather than a voluntary market-timing sale. Such transactions are common when restricted stock units vest and do not necessarily signal the insider’s view on the company’s outlook.
Insider Transaction Report
Form 4
LEVIN ARTHUR A
Director
Transactions
- Sale
Common Stock
[F1]2026-01-21$72.45/sh−1,758$127,367→ 16,562 total
Holdings
- 131,372(indirect: By Trust)
Common Stock
- 22,500(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.
Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact|2026-01-23